171 related articles for article (PubMed ID: 35115097)
1. Antithrombotic Therapy in Patients With Atrial Fibrillation After Acute Coronary Syndromes or Percutaneous Intervention.
Harskamp RE; Fanaroff AC; Lopes RD; Wojdyla DM; Goodman SG; Thomas LE; Aronson R; Windecker S; Mehran R; Granger CB; Alexander JH
J Am Coll Cardiol; 2022 Feb; 79(5):417-427. PubMed ID: 35115097
[TBL] [Abstract][Full Text] [Related]
2. Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS.
Alexander JH; Wojdyla D; Vora AN; Thomas L; Granger CB; Goodman SG; Aronson R; Windecker S; Mehran R; Lopes RD
Circulation; 2020 May; 141(20):1618-1627. PubMed ID: 32223444
[TBL] [Abstract][Full Text] [Related]
3. Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke: A Post Hoc Analysis From the AUGUSTUS Trial.
Bahit MC; Vora AN; Li Z; Wojdyla DM; Thomas L; Goodman SG; Aronson R; Jordan JD; Kolls BJ; Dombrowski KE; Vinereanu D; Halvorsen S; Berwanger O; Windecker S; Mehran R; Granger CB; Alexander JH; Lopes RD
JAMA Cardiol; 2022 Jul; 7(7):682-689. PubMed ID: 35612866
[TBL] [Abstract][Full Text] [Related]
4. Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.
Hijazi Z; Alexander JH; Li Z; Wojdyla DM; Mehran R; Granger CB; Parkhomenko A; Bahit MC; Windecker S; Aronson R; Berwanger O; Halvorsen S; de Waha-Thiele S; Sinnaeve P; Darius H; Storey RF; Lopes RD
Circulation; 2021 Mar; 143(12):1215-1223. PubMed ID: 33461308
[TBL] [Abstract][Full Text] [Related]
5. Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.
Windecker S; Lopes RD; Massaro T; Jones-Burton C; Granger CB; Aronson R; Heizer G; Goodman SG; Darius H; Jones WS; Aschermann M; Brieger D; Cura F; Engstrøm T; Fridrich V; Halvorsen S; Huber K; Kang HJ; Leiva-Pons JL; Lewis BS; Malaga G; Meneveau N; Merkely B; Milicic D; Morais J; Potpara TS; Raev D; Sabaté M; de Waha-Thiele S; Welsh RC; Xavier D; Mehran R; Alexander JH;
Circulation; 2019 Dec; 140(23):1921-1932. PubMed ID: 31557056
[TBL] [Abstract][Full Text] [Related]
6. An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial.
Lopes RD; Vora AN; Liaw D; Granger CB; Darius H; Goodman SG; Mehran R; Windecker S; Alexander JH
Am Heart J; 2018 Jun; 200():17-23. PubMed ID: 29898844
[TBL] [Abstract][Full Text] [Related]
7. Impact of prior oral anticoagulant use and outcomes on patients from secondary analysis in the AUGUSTUS trial.
Welsh RC; Dehghani P; Lopes R; Wojdyla DM; Aronson R; Granger CB; Windecker S; Vora AN; Vinereanu D; Halvorsen S; Parkhomenko A; Mehran R; Alexander JH; Goodman S
Open Heart; 2022 Feb; 9(1):. PubMed ID: 35172988
[TBL] [Abstract][Full Text] [Related]
8. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation.
Lopes RD; Heizer G; Aronson R; Vora AN; Massaro T; Mehran R; Goodman SG; Windecker S; Darius H; Li J; Averkov O; Bahit MC; Berwanger O; Budaj A; Hijazi Z; Parkhomenko A; Sinnaeve P; Storey RF; Thiele H; Vinereanu D; Granger CB; Alexander JH;
N Engl J Med; 2019 Apr; 380(16):1509-1524. PubMed ID: 30883055
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of apixaban versus vitamin K antagonists for antithrombotic therapy in patients with atrial fibrillation after acute coronary syndrome or percutaneous coronary intervention in Spain.
Rivolo S; Di Fusco M; Polanco C; Kang A; Dhanda D; Savone M; Skandamis A; Kongnakorn T; Soto J
PLoS One; 2021; 16(11):e0259251. PubMed ID: 34767564
[TBL] [Abstract][Full Text] [Related]
10. Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS trials.
Potpara TS; Mujovic N; Proietti M; Dagres N; Hindricks G; Collet JP; Valgimigli M; Heidbuchel H; Lip GYH
Europace; 2020 Jan; 22(1):33-46. PubMed ID: 31603196
[TBL] [Abstract][Full Text] [Related]
11. Antithrombotic Strategies According to Age: Insights From the AUGUSTUS Trial.
Guimarães PO; Lopes RD; Wojdyla DM; Alexander JH; Goodman SG; Aronson R; Halvorsen S; Sinnaeve P; Vinereanu D; Storey RF; Berwanger O; Windecker S; Mehran R; Granger CB; Alexander KP;
Am J Med; 2024 Jun; ():. PubMed ID: 38876331
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis of Randomized Controlled Trials.
Lopes RD; Hong H; Harskamp RE; Bhatt DL; Mehran R; Cannon CP; Granger CB; Verheugt FWA; Li J; Ten Berg JM; Sarafoff N; Gibson CM; Alexander JH
JAMA Cardiol; 2019 Aug; 4(8):747-755. PubMed ID: 31215979
[TBL] [Abstract][Full Text] [Related]
13. Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and RE-DUAL PCI trials?
Duerschmied D; Brachmann J; Darius H; Frey N; Katus HA; Rottbauer W; Schäfer A; Thiele H; Bode C; Zeymer U
Clin Res Cardiol; 2018 Jul; 107(7):533-538. PubMed ID: 29679144
[TBL] [Abstract][Full Text] [Related]
14. CHADS2, CHA2DS2-VASc and HAS-BLED as predictors of outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention.
Puurunen MK; Kiviniemi T; Schlitt A; Rubboli A; Dietrich B; Karjalainen P; Nyman K; Niemelä M; Lip GY; Airaksinen KE
Thromb Res; 2014 Apr; 133(4):560-6. PubMed ID: 24461143
[TBL] [Abstract][Full Text] [Related]
15. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial.
Vranckx P; Valgimigli M; Eckardt L; Tijssen J; Lewalter T; Gargiulo G; Batushkin V; Campo G; Lysak Z; Vakaliuk I; Milewski K; Laeis P; Reimitz PE; Smolnik R; Zierhut W; Goette A
Lancet; 2019 Oct; 394(10206):1335-1343. PubMed ID: 31492505
[TBL] [Abstract][Full Text] [Related]
16. Outcomes in Newly Diagnosed Atrial Fibrillation and History of Acute Coronary Syndromes: Insights from GARFIELD-AF.
Verheugt FWA; Ambrosio G; Atar D; Bassand JP; Camm AJ; Costabel JP; Fitzmaurice DA; Illingworth L; Goldhaber SZ; Goto S; Haas S; Jansky P; Kayani G; Stepinska J; Turpie AGG; van Eickels M; Kakkar AK;
Am J Med; 2019 Dec; 132(12):1431-1440.e7. PubMed ID: 31306621
[TBL] [Abstract][Full Text] [Related]
17. Edoxaban in atrial fibrillation patients with percutaneous coronary intervention by acute or chronic coronary syndrome presentation: a pre-specified analysis of the ENTRUST-AF PCI trial.
Vranckx P; Valgimigli M; Eckardt L; Lewalter T; Unikas R; Marin F; Schiele F; Laeis P; Reimitz PE; Smolnik R; Zierhut W; Tijssen J; Goette A
Eur Heart J; 2020 Dec; 41(47):4497-4504. PubMed ID: 32860041
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial.
Lopes RD; Al-Khatib SM; Wallentin L; Yang H; Ansell J; Bahit MC; De Caterina R; Dorian P; Easton JD; Erol C; Ezekowitz JA; Gersh BJ; Granger CB; Hohnloser SH; Horowitz J; Hylek EM; McMurray JJ; Mohan P; Vinereanu D; Alexander JH
Lancet; 2012 Nov; 380(9855):1749-58. PubMed ID: 23036896
[TBL] [Abstract][Full Text] [Related]
19. Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: An Updated Network Meta-analysis.
Lopes RD; Hong H; Harskamp RE; Bhatt DL; Mehran R; Cannon CP; Granger CB; Verheugt FWA; Li J; Ten Berg JM; Sarafoff N; Vranckx P; Goette A; Gibson CM; Alexander JH
JAMA Cardiol; 2020 May; 5(5):582-589. PubMed ID: 32101251
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials.
Gargiulo G; Goette A; Tijssen J; Eckardt L; Lewalter T; Vranckx P; Valgimigli M
Eur Heart J; 2019 Dec; 40(46):3757-3767. PubMed ID: 31651946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]